ran into serious problems -including safety concerns -that slowed progress. In his Review on p316, Mark Kay discusses how many hurdles to gene-based therapy have been tackled by improvements to vectors.
The 'traditional' mode of gene-based therapy is the delivery of a therapeutic transgene using viruses that target certain tissues and cell types.
The greatest progress with this type of therapy has been achieved using adeno-associated virus vectors -the topic of the Review from Federico Mingozzi and Katherine High on p341. The authors highlight the fact that each tissue type has its own set of challenges as a therapeutic target.
An area that shows great therapeutic promise is the combination of cell-based delivery with gene-transfer technologies. Luigi Naldini explores the wide range of applications of this mode of therapy, which is being used to tackle diseases from immunodeficiencies to cancer (Review, p301).
Approaches for monitoring and reducing insertional mutagenesis have been important developments in this field. 
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